Orchid Pharma Files Compliance Certificate for Q3 FY26 under SEBI Regulations
Orchid Pharma Limited submitted a compliance certificate for Q3 FY26, ending December 31, 2025. The certificate, issued by Registrar Abhipra Capital Limited, confirms compliance with SEBI (Depositories and Participants) Regulations, 2018. The company has requested the stock exchanges to take this on record.
This is a standard regulatory filing required by SEBI. It does not introduce any new information that is expected to influence the stock price or investor sentiment.
The announcement is a routine compliance filing and does not contain any significant financial or business updates that would impact the company's valuation or outlook.
Orchid Pharma Limited has submitted a compliance certificate for the third quarter of the financial year 2025-26, which ended on December 31, 2025. The certificate was issued by M/s. Abhipra Capital Limited, the company's Registrar and Share Transfer Agent, confirming adherence to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, as amended.
The company has requested that this intimation be taken on record by the stock exchanges. The announcement was made on January 8, 2026, and copies were sent to the National Securities Depository Limited and Central Depository Services (India) Limited.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.